Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T.

J Infect Dis. 2013 Nov 1;208(9):1464-73. doi: 10.1093/infdis/jit352. Epub 2013 Jul 29.

2.

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.

Rockwood N, Meintjes G, Chirehwa M, Wiesner L, McIlleron H, Wilkinson RJ, Denti P.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6050-9. doi: 10.1128/AAC.00480-16. Print 2016 Oct.

3.

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H.

Antimicrob Agents Chemother. 2015 Jan;59(1):38-45. doi: 10.1128/AAC.03931-14. Epub 2014 Oct 13.

4.

Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE.

Antimicrob Agents Chemother. 2013 Jul;57(7):3208-13. doi: 10.1128/AAC.02599-12. Epub 2013 Apr 29.

5.

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.

6.

Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.

Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, Capaner E.

Antimicrob Agents Chemother. 2013 Nov;57(11):5740-2. doi: 10.1128/AAC.01345-13. Epub 2013 Aug 26.

7.

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW.

Clin Infect Dis. 2009 Jun 15;48(12):1685-94. doi: 10.1086/599040.

8.

Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH.

Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8. doi: 10.1128/AAC.00693-15.

9.

Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.

Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, Shahsavari N, Emami S, Habibi M, Salamzadeh J.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1602-6. doi: 10.5588/ijtld.13.0019.

PMID:
24200276
10.

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R.

Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9. doi: 10.1128/AAC.02468-12. Epub 2013 May 20.

11.

Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.

Babalık A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildiz L, Çarpaner E.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1442-7. doi: 10.5588/ijtld.12.0771.

PMID:
24125448
12.

Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin.

Ahn C, Oh KH, Kim K, Lee KY, Lee JG, Oh MD, Kim Y, Han JS, Kim S, Lee JS, Jang IJ, Shin SG.

Perit Dial Int. 2003 Jul-Aug;23(4):362-7.

PMID:
12968844
13.

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.

Façanha MC, Gondim AM, Pinheiro VG, Barroso EC, Peloquin CA, Guerrant RL, Lima AA.

Braz J Infect Dis. 2009 Jun;13(3):210-7.

14.

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P.

Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7.

15.

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.

Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51. Epub 2007 Apr 23.

16.

Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.

Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.

Clin Ther. 2013 Feb;35(2):161-8. doi: 10.1016/j.clinthera.2013.01.003.

PMID:
23410999
17.

Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.

van Oosterhout JJ, Dzinjalamala FK, Dimba A, Waterhouse D, Davies G, Zijlstra EE, Molyneux ME, Molyneux EM, Ward S.

Antimicrob Agents Chemother. 2015 Oct;59(10):6175-80. doi: 10.1128/AAC.01193-15. Epub 2015 Jul 27.

18.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

19.

Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.

Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE.

Chest. 1998 May;113(5):1178-83.

PMID:
9596291
20.

Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE 3rd, Dartois V.

Antimicrob Agents Chemother. 2012 Jan;56(1):446-57. doi: 10.1128/AAC.05208-11. Epub 2011 Oct 10.

Supplemental Content

Support Center